Data investigation

Cheapest GLP-1 Without Insurance in 2026: Buyer's Guide

The cheapest legitimate GLP-1 in 2026 is Foundayo (oral orforglipron) or Wegovy oral pill at $149/month. This buyer's guide walks every legitimate cash-pay tier in cost-ascending order, with verified pricing, regulatory caveats, and magnitude-vs-cost comparisons.

By Eli Marsden · Founding Editor
Editorially reviewed (not clinically reviewed) · How we verify contentLast reviewed
13 min read·13 citations

This buyer’s guide is part of Weight Loss Rankings’ living editorial database — 300+ research articles and 190+ clinically-reviewed GLP-1 telehealth providers, sourced only from FDA prescribing information on DailyMed, peer-reviewed PubMed literature, and live-verified manufacturer pricing.

Cash-pay GLP-1 pricing changed dramatically in late 2025 and early 2026. NovoCare Pharmacy repriced Wegovy from $499 to $299/month for the standard pen and launched a $149/month oral pill. LillyDirect Self Pay Pharmacy launched Zepbound vials at $299-$449/month by dose tier. Eli Lilly launched Foundayo (orforglipron) at $149/month, the first oral small-molecule GLP-1, via LillyDirect and Amazon Pharmacy. This article walks every legitimate cash-pay tier in cost-ascending order, with verified pricing, regulatory caveats, and magnitude-vs-cost comparisons. Research-peptide and OTC “natural Ozempic” supplement options are deliberately excluded as not legitimate.

The honest answer

The cheapest legitimate GLP-1 in 2026 is Foundayo (oral orforglipron) at $149/month via LillyDirect or Amazon Pharmacy, followed by Wegovy oral pill at $149/month via NovoCare. Compounded semaglutide can be cheaper ($99-$300/month) but the regulatory grace period ended in early 2025 — legal status is unsettled. Patient Assistance Programs (Lilly Cares, Novo Nordisk PAP) provide free brand-name GLP-1 to uninsured patients at or below 400% of the Federal Poverty Level.

Real retail cost of GLP-1s in 2026 (the $1,300/month problem)

The list price of FDA-approved GLP-1 medications is approximately $1,000-$1,350 per month at retail without insurance, depending on the product, the dose, and the dispensing pharmacy. That is the price your local CVS, Walgreens, or Walmart will quote you at the counter for a 4-week supply of brand-name Wegovy, Zepbound, Ozempic, or Mounjaro if you walk in with a prescription and pay cash — no insurance, no manufacturer program, no coupon.

That headline number is what drove the compounded-GLP-1 telehealth industry that dominated 2023 and 2024, and what continues to drive the grey-market “research peptide” market into 2026. The good news is that the legitimate cash-pay landscape has changed materially since late 2025. The manufacturers themselves launched direct-to-patient channels at much lower prices to defend market share against compounded competitors. Costco partnered with Sesame for a member-only program. Amazon Pharmacy entered as a third Foundayo channel. The result is that the $1,300/month wall has cracks — large ones.

The legitimate cash-pay GLP-1 landscape in 2026, sorted cheapest to most expensive:

TierProductChannelMonthly cost
1Lilly Cares / Novo Nordisk PAP (income-qualified)Direct manufacturer assistance$0
2Compounded semaglutide (regulatory caveat)503A telehealth pharmacies$99-$300
3Foundayo (orforglipron oral)LillyDirect / Amazon Pharmacy$149
4Wegovy oral pill (semaglutide 25 mg oral)NovoCare Pharmacy$149
5Wegovy standard pen (0.25-2.4 mg)NovoCare Pharmacy$299
6Zepbound vials (2.5-15 mg dose tiers)LillyDirect Self Pay Pharmacy$299-$449
7Wegovy or OzempicCostco Member Prescription Program via Sesame$349 (+ $60 visit)
8Brand Wegovy / Zepbound / Ozempic / MounjaroRetail pharmacy, no insurance$1,000-$1,350

The rest of this article walks each tier in detail with the regulatory, clinical, and practical caveats. The single most important point: the cheapest legitimate FDA-approved GLP-1 in 2026 is $149/month, not $1,300/month. If you are still seeing $1,000+ quoted in old articles or at a retail pharmacy counter, the manufacturer’s direct-to-patient channel is the lever — not insurance, not a coupon, not a research peptide.

Cheapest legitimate option: Foundayo oral $149/month

Foundayo is the brand name for orforglipron, the first FDA-approved oral small-molecule GLP-1 receptor agonist. It is a non-peptide GLP-1 agonist that survives the gastric environment without needing the absorption- enhancer formulation that the oral semaglutide products require, which means once-daily oral dosing without the fasting-window protocol that Rybelsus and Wegovy oral pill demand. Eli Lilly launched Foundayo commercially in late 2025 with a deliberately aggressive direct-to- patient cash-pay price.[4]

The launch pricing per the Eli Lilly Investor Relations release of December 1, 2025:

  • $149 per month at LillyDirect Self Pay Pharmacy (lillydirect.lilly.com), Lilly’s direct-to-patient channel that ships the product nationally with cold-chain-not-required ground shipping.
  • $149 per month at Amazon Pharmacy (pharmacy.amazon.com), which operates as a U.S.-licensed mail-order pharmacy filling FDA-approved Foundayo prescriptions at parity with the LillyDirect price. Prime membership is not required.[10]

The clinical magnitude per ATTAIN-1, the pivotal Phase 3 trial that supported the FDA approval: oral orforglipron at the 36 mg once-daily dose produced approximately -11.2% placebo-adjusted body- weight reduction at week 72 in adults with obesity.[3] That sits below the FDA-approved injectables (Wegovy ~15%, Zepbound ~21% TBWL) but is meaningfully better than every other oral or non-injectable weight-loss product on the U.S. market — and the price is a fraction of the injectable cash-pay tiers.

Why Foundayo at $149 is the headline tier

  • FDA-approved, full pharmaceutical quality, brand-name product.
  • Two parallel channels (LillyDirect, Amazon Pharmacy) at the same price — competition reduces stockout risk.
  • Oral once-daily; no injection, no cold chain, no titration-related discontinuation rates.
  • Clinical magnitude (~11% TBWL) is the best of any non-injectable.
  • No FDA Drug Shortage exposure (orforglipron has never been in shortage).

See our companion piece on where to buy Foundayo for the full channel-by-channel breakdown including ship times, prescription transfer, and the LillyDirect vs Amazon Pharmacy prescriber-credential differences.

Wegovy oral pill at NovoCare ($149/month)

Novo Nordisk responded to the Foundayo launch with a parallel $149/month oral product: the Wegovy oral pill, a 25 mg semaglutide once-daily oral tablet dispensed through NovoCare Pharmacy, Novo Nordisk’s direct-to-patient channel.[5] This is the same active ingredient as injectable Wegovy and Ozempic (semaglutide), reformulated for oral administration with the absorption-enhancer SNAC that is also used in Rybelsus — the oral semaglutide product Novo Nordisk has marketed for type 2 diabetes since 2019.

The clinical magnitude data on the Wegovy oral pill at 25 mg is closer to injectable semaglutide than Rybelsus 14 mg was: trial data supporting the FDA expanded approval showed weight-loss outcomes comparable to the 2.4 mg subcutaneous Wegovy ladder in head-to-head comparison, with the oral product avoiding the injection-site reactions and the autoinjector titration-discontinuation rates. The protocol is once-daily oral on an empty stomach with no food or other oral medication for 30 minutes afterward — the standard SNAC absorption-window protocol.

Practical considerations for the Wegovy oral pill at NovoCare:

  • Channel: NovoCare Pharmacy direct-to-patient (novocare.com). Single-pipeline dispensing — not available at Costco or Amazon Pharmacy at this price tier as of 2026.
  • Prescription: Required. NovoCare partners with telehealth clinicians who can issue the prescription if you do not have a treating prescriber.
  • Protocol: Once-daily oral on empty stomach; 30 minutes before food, beverages other than water, and other oral medications.
  • Storage: Room temperature; no refrigeration; no cold-chain shipping.
  • Eligibility: Verified cash-pay (uninsured or insurance-declined). Insurance with Wegovy coverage routes through the standard pharmacy channel at the negotiated insurance price.

Compounded semaglutide: $99-$300/month with regulatory caveats

Compounded semaglutide can be cheaper than Foundayo or the Wegovy oral pill — the floor sits at $99/month for the cheapest providers, with the median in the $150-$250/month range. This is real pharmaceutical-grade semaglutide compounded by 503A state-licensed pharmacies from FDA-registered API supply, dispensed against a prescription from a telehealth clinician. Our companion piece verifies every provider at the floor price against licensing, pharmacy partner, and dose.

The regulatory landscape is where the asterisk lives. The FDA Drug Shortage list declared injectable semaglutide resolved on February 21, 2025. Per FDA enforcement-discretion policy, the deadlines that followed were:

  • April 22, 2025: 503A state-licensed pharmacy enforcement-discretion ended for compounded semaglutide.[7]
  • May 22, 2025: 503B outsourcing-facility enforcement- discretion ended for compounded semaglutide.[7]

After those dates, broad commercial compounded semaglutide sits outside the FDA enforcement-discretion framework. Many telehealth providers continue dispensing under narrow patient-specific 503A clinical- necessity authority (e.g., documented allergy to a Wegovy inactive ingredient, documented dose strength not available in the approved product). The legal status varies by state board of pharmacy interpretation. The product itself is pharmaceutical-grade and dispensed through a licensed pharmacy — but the “is this commercial compounding still permitted” question is unsettled.[8]

Compounded semaglutide buyer checklist

  • LegitScript Healthcare Merchant Certification on the telehealth provider.
  • NABP “.pharmacy” domain, VIPPS accreditation, or NABP non-recommendation lookup on the dispensing pharmacy.
  • FDA-registered API supplier for the bulk semaglutide.
  • USP <797> sterile-compounding standards documented.
  • Patient-prescriber relationship with a licensed clinician — not just a checkbox intake.
  • Refund policy and adverse-event reporting pathway disclosed in writing.

The honest framing: at $149/month for legitimate brand Foundayo or Wegovy oral pill, the cost gap that drove the compounded semaglutide market in 2023-2024 has narrowed dramatically. The compounded floor ($99/month) is still cheaper, but the difference is $50/month rather than the $1,200/month it used to be. Many readers find the regulatory certainty of the brand channels worth the $50 difference.

Costco Member Prescription Program via Sesame

Costco partnered with Sesame, a cash-pay telehealth and pharmacy marketplace, to offer FDA-approved brand Wegovy and Ozempic to Costco members at $349 per month plus a $60 Sesame telehealth visit fee for the prescription.[9] The program is the Costco Member Prescription Program (CMPP); enrollment is through sesamecare.com’s Costco-member channel.

CMPP characteristics:

  • Eligibility: Costco Gold Star, Business, or Executive membership.
  • Visit fee: $60 per Sesame visit for the prescription (separate from the drug cost).
  • Drug cost: $349 per month for Wegovy or Ozempic, regardless of dose ladder position.
  • Product: FDA-approved brand Wegovy / Ozempic from Novo Nordisk; full pharmaceutical quality.
  • Fulfillment: Costco Pharmacy or mail-order via Sesame’s partner network.

Where CMPP sits in the cost stack: more expensive than the $149 oral tiers (Foundayo, Wegovy oral pill) and more expensive than the $299 Wegovy injectable pen at NovoCare Pharmacy. CMPP is most useful when you specifically want brand Wegovy or Ozempic injectable, have a Costco membership, and prefer the Sesame telehealth workflow over enrolling directly with NovoCare.

Wegovy NovoCare pen + LillyDirect Zepbound vials ($299-$449)

The injectable cash-pay tiers from the manufacturers’ direct channels:

Wegovy standard pen at NovoCare: $299/month

NovoCare Pharmacy dispenses the standard Wegovy autoinjector pen (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg dose ladder) at a flat $299 per month regardless of dose. This is the same physical product as the retail Wegovy pen — full pharmaceutical quality, cold-chain ground shipping, four single-use pens per month. The price was repriced down from $499/month in late 2025 as Novo Nordisk responded to the Foundayo launch and the broader cash-pay market shift.[5]

LillyDirect Self Pay Zepbound vials: $299/$399/$449

LillyDirect Self Pay Pharmacy dispenses Zepbound in single-dose vial format at the dose-tier pricing established in the Eli Lilly Investor Relations release of December 1, 2025:[4]

  • $299/month for the 2.5 mg single-dose vial (titration start dose).
  • $399/month for the 5 mg single-dose vial.
  • $449/month for the 7.5 mg, 10 mg, 12.5 mg, and 15 mg single-dose vials.

The vial format requires a syringe draw rather than the prefilled autoinjector pen, but the product is genuine brand Zepbound from the FDA-approved Eli Lilly manufacturing chain, with all USP quality testing intact. A prescription is required; LillyDirect routes through partnered telehealth clinicians if you do not have a treating prescriber.

Patient Assistance Programs + copay savings cards

Two parallel manufacturer programs serve uninsured or insurance-declined patients at the lowest income levels: the Lilly Cares Foundation Patient Assistance Program (Zepbound, Mounjaro) and the Novo Nordisk Patient Assistance Program (Wegovy, Ozempic, Saxenda, Rybelsus).[11][12]

Lilly Cares + Novo Nordisk PAP eligibility

Both programs share an income-and-status framework:

  • Income: At or below 400% of the Federal Poverty Level. For 2026, that is roughly $62,600 for a single-person household in the 48 contiguous states and $128,600 for a family of four; higher thresholds apply in Alaska and Hawaii.[13]
  • Insurance: Uninsured, or insured with the GLP-1 documented as not covered after appeal.
  • Documentation: Patient application, prescriber attestation, proof of income (recent tax return or pay stubs), proof of uninsured status.
  • Approval term: 12 months of free brand-name supply per approval, renewable annually.

For eligible patients, this is the absolute cheapest legitimate path to brand-name GLP-1 in 2026 — $0/month. The income threshold and the uninsured-status requirement are real and audited; the program is not a discount card for the broader market.

Manufacturer copay savings cards

For commercial-insurance patients with GLP-1 coverage subject to a high copay or coinsurance, manufacturer copay savings cards can bring out-of-pocket cost to as low as $25 per month:

  • Wegovy Savings Card (Novo Nordisk) — reduces eligible commercial-insurance out-of-pocket cost for Wegovy. Eligibility excludes Medicare, Medicaid, and other federal-program beneficiaries.
  • Zepbound Savings Card (Eli Lilly) — same structure for Zepbound; excludes federal-program beneficiaries.
  • Ozempic Savings Card (Novo Nordisk) — for type 2 diabetes patients with commercial coverage.
  • Mounjaro Savings Card (Eli Lilly) — for type 2 diabetes patients with commercial coverage.

See our GLP-1 cash-pay coupon channel guide for the full breakdown including GoodRx, Sam’s Club Plus Pharmacy, and the channel-by-channel comparison for any combination of insurance status and drug.

What we don’t recommend (research peptides, OTC supplements)

Two categories of products advertise GLP-1-class weight-loss outcomes at prices far below the legitimate tiers above. Neither belongs in this buyer’s guide.

Chemistry-supply websites sell lyophilized semaglutide and tirzepatide vials at $80-$300 per vial, labeled “for research use only, not for human consumption.” These products have no FDA quality testing — no USP identity, no purity, no sterility, no endotoxin testing, no dose-accuracy verification. The “research use only” disclaimer is the seller’s legal shield against the distribution charge; it does not legalize personal-use injection by the buyer. Customs routinely seizes inbound shipments. Documented dosing errors up to 20-fold the intended dose have been reported with similar non-brand lyophilized GLP-1 products.

At $149/month for legitimate FDA-approved Foundayo or Wegovy oral pill, the cost gap that drove the research-peptide market has closed. See our full research-peptide debunker for the regulatory, quality, and enforcement detail.

Berberine, apple cider vinegar gummies, GLP-1 patches, sublingual GLP-1 sprays, and the various “natural Ozempic” supplements marketed at $30-$80 per month produce zero to negligible weight loss in controlled studies. The published berberine meta-analysis shows roughly 2-4 lbs of weight reduction over 12 weeks — versus the 35-50 lbs documented in STEP-1 and SURMOUNT-1 for FDA-approved semaglutide and tirzepatide.[1][2] There is no transdermal, sublingual, or oral-spray formulation of any GLP-1 receptor agonist with FDA approval or with documented bioequivalence to the FDA-approved subcutaneous or oral products. The $149/month Foundayo or Wegovy oral pill is the cheapest real GLP-1; the $30/month supplement is not a GLP-1 at all.

Cost-per-pound-lost: magnitude vs cost

The headline price is only half the picture. The other half is the clinical magnitude — how much weight loss the product produces at its labeled maximum dose. Combining the two gives a cost-per- percentage-point of total body weight lost (TBWL), which is the most useful single metric for comparing options.

Magnitude comparison

Weight-loss magnitude — FDA-approved GLP-1s at labeled maximum dose[1][2][3]

  • Berberine (supplement, 12 wk)2 % TBWL
    approximate; not a GLP-1
  • Foundayo (orforglipron 36 mg oral, ATTAIN-1)11 % TBWL
  • Wegovy (semaglutide 2.4 mg SC, STEP-1)15 % TBWL
  • Zepbound (tirzepatide 15 mg SC, SURMOUNT-1)21 % TBWL
Weight-loss magnitude — FDA-approved GLP-1s at labeled maximum dose

Combining magnitude with the 12-month cash-pay cost for a 180-lb starting weight (where TBWL converts to absolute pounds):

Product (max dose)TBWLPounds lost (180 lb start)12-mo cost$ per lb lost
Foundayo oral 36 mg ($149/mo)~11%~20 lb$1,788~$89/lb
Wegovy oral pill 25 mg ($149/mo)~15%~27 lb$1,788~$66/lb
Wegovy pen 2.4 mg ($299/mo)~15%~27 lb$3,588~$133/lb
Zepbound vial 15 mg ($449/mo)~21%~38 lb$5,388~$143/lb
Lilly Cares / Novo Nordisk PAP~15-21%~27-38 lb$0$0/lb

The Wegovy oral pill at $149/month is the best cost-per-pound on the cash-pay grid, narrowly edging Foundayo on the magnitude axis. Zepbound produces the largest absolute weight loss but at the highest absolute cost per pound. PAPs win on every dimension for income-qualified patients. Run your own numbers with our GLP-1 cost-per-pound calculator and the GLP-1 savings calculator for your specific starting weight, target weight, and insurance situation.

Bottom line

  • The cheapest legitimate FDA-approved GLP-1 in 2026 is $149/month — Foundayo (oral orforglipron) via LillyDirect or Amazon Pharmacy, or Wegovy oral pill via NovoCare Pharmacy.
  • Compounded semaglutide can be cheaper ($99-$300/month) but the FDA enforcement-discretion grace period ended in April-May 2025; the legal status of broad commercial compounding is unsettled.
  • The Wegovy standard pen at NovoCare is $299/month (repriced from $499 in late 2025); LillyDirect Self Pay Zepbound vials are $299/$399/$449/month by dose tier per the Lilly IR Dec 1, 2025 release.
  • Costco Member Prescription Program via Sesame offers brand Wegovy or Ozempic at $349/month plus a $60 Sesame visit fee, for Costco members.
  • Lilly Cares Foundation and Novo Nordisk PAP provide free brand-name GLP-1 to uninsured patients at or below 400% of the Federal Poverty Level. For eligible patients this is the absolute lowest legitimate price.
  • Research-chemical peptides and OTC “natural Ozempic” supplements are not in the comparison. The first is illegal and has no FDA quality testing; the second has no weight-loss effect comparable to a real GLP-1.
  • See our GLP-1 pricing index for the live-tracking dataset that underpins this article.

Frequently asked questions

References

  1. 1.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. STEP-1. Semaglutide 2.4 mg subcutaneous once-weekly produced -14.9% mean body-weight reduction versus -2.4% placebo at week 68 in 1,961 adults with overweight or obesity. This is the canonical magnitude benchmark cited throughout the article for what FDA-approved injectable semaglutide produces at the labeled maximum dose. N Engl J Med. 2021. PMID: 33567185.
  2. 2.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. SURMOUNT-1. Subcutaneous tirzepatide 5 mg, 10 mg, and 15 mg once-weekly produced mean body-weight reductions of -15.0%, -19.5%, and -20.9% respectively versus -3.1% placebo at week 72 in 2,539 adults with obesity. This is the canonical magnitude benchmark for FDA-approved injectable tirzepatide cited throughout the article. N Engl J Med. 2022. PMID: 35658024.
  3. 3.Wharton S, Ahmad NN, Aronne LJ, Connery L, Eriksson M, Hsia DS, Kahan S, Knop FK, Lyu J, Petrini M, Robins D, Yokote K, Zhang S, Wang J, Coskun T, Garvey WT; ATTAIN-1 Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. ATTAIN-1. Once-daily oral orforglipron at the 36 mg dose produced approximately -11.2% placebo-adjusted body-weight reduction at week 72 in adults with obesity. This is the canonical magnitude benchmark for the new oral GLP-1 class cited throughout the article; orforglipron is the active ingredient in Foundayo. N Engl J Med. 2025. PMID: 40960239.
  4. 4.Eli Lilly and Company, Investor Relations. Lilly announces LillyDirect Self Pay Pharmacy Zepbound vial pricing: $299 for 2.5 mg, $399 for 5 mg, $449 for 7.5 mg and higher dose vials. Launch of Foundayo (orforglipron) at $149 per month via LillyDirect Self Pay Pharmacy and Amazon Pharmacy. Press release December 1, 2025. Eli Lilly and Company Investor Relations. 2025. https://investor.lilly.com/news-releases
  5. 5.Novo Nordisk Inc. NovoCare Pharmacy direct-to-patient cash-pay program. Wegovy standard pen (0.25 mg to 2.4 mg dose ladder) repriced from $499 to $299 per month in late 2025. Wegovy oral pill (semaglutide 25 mg oral tablet) launched at $149 per month in parallel. Single direct-to-patient pipeline; verification of cash-pay eligibility at enrollment. NovoCare Pharmacy. 2026. https://www.novocare.com
  6. 6.U.S. Food and Drug Administration. Declaratory Order: Resolution of Shortages of Tirzepatide. December 19, 2024. FDA reconfirmed the tirzepatide shortage was resolved. Enforcement-discretion deadlines set for state-licensed 503A pharmacies (February 18, 2025) and 503B outsourcing facilities (March 19, 2025) for compounded tirzepatide. U.S. Food and Drug Administration. 2024. https://www.fda.gov/media/184606/download
  7. 7.U.S. Food and Drug Administration. FDA Drug Shortages: Semaglutide Injection — Resolved. Semaglutide injectable shortage declared resolved February 21, 2025. 503A state-licensed pharmacy enforcement-discretion for compounded semaglutide ended April 22, 2025; 503B outsourcing-facility enforcement-discretion ended May 22, 2025. After these dates, broad commercial compounded semaglutide sits outside the enforcement-discretion framework; only narrow patient-specific 503A clinical-necessity compounding remains. U.S. Food and Drug Administration. 2025. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Semaglutide%20Injection
  8. 8.U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. Agency statement explaining the post-shortage compounding policy framework for tirzepatide and semaglutide, including the section 503A and 503B enforcement-discretion timelines. U.S. Food and Drug Administration. 2025. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  9. 9.Costco Wholesale Corporation, Sesame Inc. Costco Member Prescription Program (CMPP) GLP-1 access via Sesame. Costco members pay $349 per month for Wegovy and Ozempic through the Costco-Sesame partnership, plus a $60 Sesame telehealth visit fee for the prescription. Available to Costco Gold Star, Business, and Executive members. Pricing reflects the negotiated Costco member price as of 2026. Costco Member Prescription Program. 2026. https://www.costco.com/pharmacy-prescriptions.html
  10. 10.Amazon Pharmacy. Amazon Pharmacy Foundayo (orforglipron) cash-pay availability at $149 per month. Amazon Pharmacy operates as a U.S. licensed mail-order pharmacy filling FDA-approved Foundayo prescriptions at parity with the LillyDirect Self Pay launch price. Prescription required; Prime membership not required for the cash-pay price. Amazon Pharmacy. 2026. https://pharmacy.amazon.com
  11. 11.Lilly Cares Foundation, Inc. Lilly Cares Patient Assistance Program. Uninsured patients at or below 400% of the Federal Poverty Level may qualify for free Zepbound and Mounjaro. Requires patient application, prescriber attestation, proof of income, and proof of uninsured status. Approval typically grants a 12-month supply, renewable annually. The most cost-effective legitimate path to brand-name GLP-1 for eligible patients. Lilly Cares Foundation. 2026. https://www.lillycares.com
  12. 12.Novo Nordisk Inc. Novo Nordisk Patient Assistance Program (PAP). Uninsured patients at or below 400% of the Federal Poverty Level may qualify for free Wegovy, Ozempic, Saxenda, and Rybelsus. Same eligibility framework as Lilly Cares: patient application, prescriber attestation, proof of income, and proof of uninsured status. 12-month supply per approval, renewable. Novo Nordisk Patient Assistance Program. 2026. https://www.novonordisk-us.com/patients/help-with-medication-costs.html
  13. 13.U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation. 2026 Poverty Guidelines (Federal Poverty Level reference tables). The 100% FPL baseline for a single-person household in the 48 contiguous states is approximately $15,650 for 2026; 400% FPL is approximately $62,600 for a single person and $128,600 for a family of four. Higher thresholds apply in Alaska and Hawaii. Used by Lilly Cares, Novo Nordisk PAP, and ACA premium-tax-credit eligibility. U.S. Department of Health and Human Services ASPE. 2026. https://aspe.hhs.gov/topics/poverty-economic-mobility/poverty-guidelines

Pricing verification. Foundayo $149/month and LillyDirect Self Pay Zepbound $299/$399/$449/month per the Eli Lilly Investor Relations release of December 1, 2025. NovoCare Pharmacy Wegovy oral pill $149/month and Wegovy standard pen $299/month per Novo Nordisk launch pricing 2026. Costco CMPP $349/month via Sesame. Compounded semaglutide floor $99/month per the live verification in /research/cheapest-compounded-semaglutide. All FDA regulatory dates verified against the FDA Drug Shortage list and the FDA Declaratory Order of December 19, 2024. PMIDs 33567185 (STEP-1), 35658024 (SURMOUNT-1), and 40960239 (ATTAIN-1) verified live via PubMed E-utilities esummary on 2026-05-23.

Important disclaimer. This article is educational information only — not medical advice, not legal advice, and not a substitute for consultation with a licensed prescriber. Cash-pay GLP-1 pricing is a YMYL (Your Money or Your Life) topic. Every regulatory and clinical claim in this article is anchored to a primary source (FDA, PubMed, manufacturer Investor Relations) and should be independently verified by your prescriber. Weight Loss Rankings does not prescribe, dispense, or endorse any specific compounding pharmacy or grey-market product. Pricing is current as of the publication date and changes — see the linked GLP-1 pricing index for the live dataset.